Friday, 14 Jun 2019

You are here

RheumNow Week in Review – Medical School Advice (9.7.18)

Dr. Jack Cush reviews news and journal articles from the past week on RheumNow.com.

  1. Methotrexate's Low Efficacy in Cutaneous Psoriasis  
  2. Usual Allopurinol Doses Insufficient in CKD Patients  
  3. Tocilizumab Equals other Biologics in Cardiovascular Risk  
  4. CRA Recommendations for Lupus Assessment and Monitoring 
  5. Advice for a Student starting Medical School - 3 important lessons: 1) Often the most important thing we give a patient is not what we think it is; 2) Much of what you are taught is wrong; 3) Keep a sunshine folder. #SGU White Coat ceremony https://t.co/jI9KdNaGXY

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA

EULAR 2019 Report – Day 2

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.